Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of amlitelimab monotherapy in adults with moderate-to-severe atopic dermatitis
MOH_2024-01-01_013146Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amlitelimab in atopic dermatitis (AD) (3 arms), sponsored by Sanofi. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on MOH_2024-01-01_013146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-01_013146.